β-Glucan attenuates inflammatory responses in oxidized LDL-induced THP-1 cells via the p38 MAPK pathway.

S Wang,H Zhou,T Feng,R Wu,X Sun,N Guan,L Qu,Z Gao,J Yan,N Xu,J Zhao,C Qi

DOI: https://doi.org/10.1016/j.numecd.2013.09.019

2013-01-01

Abstract:AIM:To investigate the immunomodulatory effects of β-(1,3/1,6)-d-glucan on atherosclerosis as well as on the molecular mechanisms of its transition. METHODS AND RESULTS:Human monocytic leukemia (THP-1) cells were differentiated into the macrophage phenotype by incubation with oxLDL in the absence or presence of β-glucan. β-glucan attenuated CD86 and CD80 expression and simultaneously reduced secretion of the inflammatory cytokines IL-2, IL-8, IL-12, TNF-α and IFN-γ. Western blot analysis showed that oxLDL treatment induced phosphorylation of p38 MAPK and ERK1/2 in PMA-differentiated THP-1 cells. However, β-glucan inhibited p38 MAPK activation. In experiments with monocytes derived from healthy donors, β-glucan inhibited IL-8, IL-12 and TNF-α production. The anti-inflammatory effects of β-glucan were also observed in atherosclerotic plaque cells. CONCLUSIONS:β-glucan inhibited oxLDL-induced pro-inflammatory effects in macrophages via regulation of p38 MAPK phosphorylation. This novel finding may provide insight for new therapeutic strategies.